芬内克制药公司部分偿还其未偿还的可转换债务融资

2024-12-19 19:24

Fennec Pharmaceuticals (TSX:FRX:CA) has made partial repayment of $13 million of the approximately $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management. This early partial repayment was financed entirely with available cash.
Post repayment, the convertible debt facility with Petrichor will be approximately $19 million and maintain a maturity of September 2027.
The partial repayment will save approximately $1.5 million in future annual interest payments and eliminate potential dilutive shares.
As previously reported in Fennec’s third quarter 2024 earnings and inclusive of this announcement, the Company anticipates that its cash, cash equivalents and investment securities will be sufficient to fund planned operations into 2026.

More on Fennec Pharmaceuticals